Molecular design of hybrid tumour necrosis factor-α II: The molecular size of polyethylene glycol-modified tumour necrosis factor-α affects its antitumour potency

British Journal of Cancer

Volumn 74, Issue 7, 1996, Pages 1090-1095

  Tsutsumi, Y ^a   Tsunoda, S ^a   Kamada, H ^a   Kihira, T ^a   Nakagawa, S ^a   Kaneda, Y ^a   Kanamori, T ^b   Mayumi, T ^a  

^a OSAKA UNIVERSITY   (Japan)

^b MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Degree of modification; Molecular design; Molecular size; Molecular weight; Polyethylene glycol; Tumour necrosis factor

Indexed keywords

MACROGOL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; HUMAN; HUMAN CELL; HYBRID; MALE; MOLECULAR SIZE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; STRUCTURE ACTIVITY RELATION;

EID: 0029786093     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.495     Document Type: Article

References (26)

1. BLICK M, SHERWIN SA, ROSENBLUM M AND GUTTERMAN J. (1987). Phase I study of recombinant human tumour necrosis factor in cancer patients. Cancer Res., 47, 2986 2989.
2. BRAUNSCHWEIGER PG, JOHNSON CS, KUMAR N, ORD V AND FURMANSKI P. (1988). Antitumor effects of recombinant human interleukin 1α in RIF-1 and Panc02 solid tumors. Cancer Res., 48, 6011 6016.
3. CARSWELL EA, OLD LJ, KASSEL SG, FIORE N AND WILLIAMSON B. (1975). An endotoxin-induced serum factor that causes necrosis of tumours. Proc. Natl Acad. Sci. USA, 72, 3666 3670.
4. CREAVEN PJ, PLAGER JE, DUPERE S, HUBEN RP, TAKITA H, MITTLEMAN A AND PROEFROCK A. (1987). Phase 1 clinical trial of recombinant human tumour necrosis factor. Cancer Chemother. Pharmacol., 20, 137 144.
5. DEBS RJ, FUCHS HJ, PHILIP R, BRUNETTE EN, DUZGUNES N, SHELLITO JE, LIGGITT D AND PATTON JR. (1990). Immunomodulatory and toxic effects of free and liposome-encapsulated tumour necrosis factor α in rats. Cancer Res., 50, 375 380.
6. HARANAKA K, SATOMI N AND SAKURAI A. (1984). Antitumour activity of murine tumour necrosis factor (TNF) against transplanted murine tumours and heterotransplanted human tumours in nude mice. Int. J. Cancer, 34, 263-267.
7. HERSHFIELD MS, CHAFFEE S, KORO-JOHNSON L, MARY A, SMITH AA AND SHORT SA. (1991). Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc. Natl Acad. Sci. USA, 88, 7185 7189.
8. IMOTO H, SAKAMURA Y, OHKOUCHI K, ATSUMI R, TAKAKURA Y, SEZAKI H AND HASHIDA M. (1992). Disposition characteristics of macromolecules in the perfused tissue-isolated tumour preparation. Cancer Res., 52, 4396 4401.
9. KATRE NV, KNAUF MJ AND LAIRD WJ. (1987). Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc. Natl Acad. Sci. USA, 84, 1487 1491.
10. KIMURA K, TAGUCHI T, URUSHIZAKI I, OHNO R, ABE O, FURUE H, HATTORI T, ICHIHASHI K, MAJIMA H, NIITANI H, OTA K, SAITO T, SUGA S, SUZUKI Y, WAKUI A AND YAMADA K. (1987). Phase I study of recombinant human tumour necrosis factor. Cancer Chemother. Pharmacol., 20, 223 229.
11. LIENARD D, EWALENKO P, DELMOTTE JJ, RENARD N AND LEJEUNE FJ. (1992). High-dose recombinant tumour necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol., 10, 52 60.
12. MORITZ T, NIEDERLE N, BAUMANN J, MAY D, KURSCHEL E, OSIEK R, KEMPENI J, SCHLICK E AND SCHMIDT CG. (1989). Phase I study of recombinant human tumour necrosis factor alpha in advanced malignant disease. Cancer Immunol. Immunother., 29, 144-150.
13. NOBUHARA M, KANAMORI T, ASHIDA Y, OGINO H, HORISAWA Y, NAKAYAMA K, ASAMI T, IKETANI M, NODA K, ANDOH S AND KURIMOTO M. (1987). The inhibition of neoplastic cell proliferation with human natural tumour necrosis factor. Jpn J. Cancer Res., 78, 193-201.
14. PFREUNDSCHUH MG, STEINMETZ HT, TUSCHEN R, SCHENK V, DIEHL V AND SCHAADT M. (1989). Phase I study of intratumoural application of recombinant human tumour necrosis factor. Eur. J. Cancer Clin. Oncol., 25, 379-388.
15. SCHILLER JH, WITT PL, STORER B, ALBERTI D, TOMBES MB, ARTZOOMANIAN R, BROWN RR, PROSTOR RA, VOSS SD AND SPROGGS DR. (1992). Clinical and biologic effects of combination therapy with gamma-interferon and tumour necrosis factor. Cancer, 69, 562 571.
16. SMITH JW, URBA WJ, CLARK JW, LONGO DL, FARRELL M, CREEKMORE SP, CONLON KC, JAFFE H AND STEIS RG. (1991). Phase I evaluation of recombinant tumour necrosis factor given in combination with recombinant interferon-gamma. J. Immunother., 10, 355-362.
17. SPRIGGS DR, SHERMAN ML, MICHIE H, ARTHUR KA, IMAMURA K, WILMORE D, FRELIII E AND KUFE DW. (1988). Recombinant human tumour necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J. Natl Cancer Inst., 80, 1039-1044.
18. TSUTSUMI Y, KIHIRA T, TSUNODA S, KUBO K, MIYAKK M, KANAMORI T, NAKAGAWA S AND MAYUMI T. (1994). Intravenous administration of polyethylene glycol-modified tumour necrosis factor-α completely regressed the solid tumour in the Meth-A murine sarcoma model. Jpn J. Cancer Res., 85, 1185 1188.
19. TSUTSUMI Y, KIHIRA T, TSUNODA S, KANAMORI T, NAKAGAWA S AND MAYUMI T. (1995a) Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its antitumour potency. Br. J. Cancer, 71, 963-968.
20. TSUTSUMI Y, KIHIRA T, TSUNODA S, OKADA N, KANEDA Y, MIYAKE M, OHSUGI Y, NAKAGAWA S AND MAYUMI T. (1995b). Polyethylene glycol-modification of interleukin-6 enhances its thrombopoietic activity. J. Control. Release, 33, 447 451.
21. TSUTSUMI Y, NAKAGAWA S AND MAYUMI T. (1995c). Bioconjugate of bioactive proteins for clinical application. Drug. Delivery. System., 10, 75-84.
22. UMENO H, WATANABE N, YAMAUCHI N, TSUJI N, OKAMOTO T AND NIITSU Y. (1994). Enhancement of blood stasis and vascular permeability in Meth-A tumours by administration of hyperthermia in combination with tumour necrosis factor. Jpn J. Cancer Res., 85, 325-330.
23. YAMAZAKI S, ONISHI E, ENAMI K, NAYORI K, KOHASE M, SAKAMOTO H, TANOUCHI M AND HAYASHI H. (1986). Proposal of standardized methods and reference for assaying recombinant human tumour necrosis factor. Jpn J. Med. Sci. Biol., 39, 105-118.
24. YANG SC, GRIMM EA, PARKINSON DR, CARINHAS J, FRY KD, MENDIGUREN RA, LICCIARDELLO J, OWEN S Lb, HONG WK AND ROTH JA. (1991). Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumour necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial. Cancer Res., 51, 3669-3676.
25. YOSHINAGA K, SHAFER SG AND HARRIS JM. (1987). Effects of polyethylene glycol substitution on enzyme activity. J. Bioact. Compatible Polymers, 2, 49-56.
26. ZIMMERMAN RJ, GAUNY S, CHAN A, LANDRE P AND WINKELHAKE JL. (1989). Sequence dependence of administration of human recombinant tumour necrosis factor and interleukin-2 in murine tumour therapy. J. Natl Cancer Inst., 81, 227-231.